Related Experiment Video

Updated: Aug 24, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Effect of fluvastatin therapy on coronary flow reserve in patients with hypercholesterolemia

Kohei Fujimoto1, Takeshi Hozumi, Hiroyuki Watanabe

  • 1Department of Internal Medicine and Cardiology, Osaka City University Medical School, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.

The American Journal of Cardiology
|May 29, 2004
PubMed

Insights

Fluvastatin therapy significantly improved coronary microcirculation in hypercholesterolemia patients. This lipid-lowering treatment enhanced coronary flow reserve, indicating better heart blood flow.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Imaging

Background:

  • Hypercholesterolemia is a major risk factor for cardiovascular disease.
  • Impaired coronary microcirculation contributes to adverse cardiac events in hypercholesterolemia.
  • Lipid-lowering therapies are crucial for managing hypercholesterolemia and its complications.

Purpose of the Study:

  • To evaluate the effect of fluvastatin on coronary flow reserve (CFR) in patients with hypercholesterolemia.
  • To assess the impact of fluvastatin therapy on coronary microcirculation.
  • To determine if lipid-lowering treatment improves myocardial perfusion.

Main Methods:

  • Transthoracic Doppler echocardiography was used to measure CFR.
  • Patients with hypercholesterolemia received fluvastatin therapy for 3 months.
  • CFR was assessed before and after the treatment period.

Main Results:

  • Coronary flow reserve (CFR) showed a significant increase after 3 months of fluvastatin therapy.
  • The study demonstrated improvement in coronary microcirculation.
  • Lipid-lowering treatment with fluvastatin positively impacted myocardial perfusion.

Conclusions:

  • Fluvastatin therapy effectively improves coronary microcirculation in patients with hypercholesterolemia.
  • Enhanced coronary flow reserve suggests a beneficial effect of fluvastatin on cardiac hemodynamics.
  • Lipid-lowering treatment represents a viable strategy to improve microvascular function in hypercholesterolemia.

More Related Videos

Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice05:07

Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice

Published on: August 25, 2023

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...